Side Effects of Interferon-α Therapy

Abstract

Aim

Interferon-α (IFN-α) has been extensively explored for its efficacy in various disease conditions and is currently used as a standard treatment in several of these. Its use is accompanied by a wide variety of possible side effects. These side-effects may hamper reaching and maintaining the dose needed for maximal therapeutic effect while their occurrence can outweigh clinical benefit of IFN-α treatment. This review addresses the toxicity profile of IFN-α, the presumed pathophysiology of the different side effects and the strategies to handle these.

Methods

Computerized searches were used and cross-references of articles and books were checked.

Results

Adverse effects due to IFN-α have been described in almost every organ system. Many side-effects are clearly dose-dependent. Taken together, occurrence of flu-like symptoms, hematological toxicity, elevated transaminases, nausea, fatigue, and psychiatric sequelae are the most frequently encountered. Although insight in the mechanisms accounting for IFN-α-related toxicities has improved in recent years, much remains to be elucidated. Guidelines on the management of these untoward sequelae are mostly based on clinical experience, while many side-effects can only be adequately handled by dose adjustment or cessation of treatment.

Conclusion

Further research on the mechanisms underlying both therapeutic effects and adverse events is warranted. Hopefully, this will lead to better identification of those patients who are likely to benefit from treatment without experiencing severe toxicities.

This is a preview of subscription content, access via your institution.

References

  1. 1

    JM Kirkwood JG Ibrahim VK Sondak J Richards LE Flaherty MS Ernstoff et al. (2000) ArticleTitleHigh- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 IssueID12 2444–58 Occurrence Handle10856105 Occurrence Handle1:CAS:528:DC%2BD3cXkvFWrsbo%3D

    PubMed  CAS  Google Scholar 

  2. 2

    JM Kirkwood C Bender S Agarwala A Tarhini J Shipe-Spotloe B Smelko et al. (2002) ArticleTitleMechanisms and management of toxicities associated with high-dose Interferon Alfa-2b therapy J Clin Oncol 20 IssueID3 3703–18 Occurrence Handle12202672 Occurrence Handle1:CAS:528:DC%2BD38XntVyns78%3D

    PubMed  CAS  Google Scholar 

  3. 3

    EM Messing J Manola G Wilding K Propert J Fleischmann ED Crawford et al. (2003) ArticleTitlePhase III study of interferon alfa as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Trial J Clin Oncol 21 IssueID7 1214–22 Occurrence Handle10.1200/JCO.2003.02.005 Occurrence Handle12663707 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWqsL8%3D

    Article  PubMed  CAS  Google Scholar 

  4. 4

    BW Hancock K Wheatley S Harris N Ives G Harrison JM Horsman et al. (2004) ArticleTitleAdjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research Randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma J Clin Oncol 22 IssueID1 23–61

    Google Scholar 

  5. 5

    CB Saper CD Breder (1994) ArticleTitleThe neurologic basis of fever N Engl J Med 330 IssueID26 1880–6 Occurrence Handle10.1056/NEJM199406303302609 Occurrence Handle7832832 Occurrence Handle1:STN:280:DyaK2c3lsV2ktg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  6. 6

    CA Dinarello HA Bernheim GW Duff HV Le TL Nagabhushan NC Hamilton et al. (1984) ArticleTitleMechanisms of fever induced by recombinant interferon J Clin Invest 74 IssueID3 906–13 Occurrence Handle6590569 Occurrence Handle1:CAS:528:DyaL2cXlsV2mtL4%3D Occurrence Handle10.1172/JCI111508

    PubMed  CAS  Article  Google Scholar 

  7. 7

    CW Hendrix BG Petty A Woods SK Kuwahara FR Witter W Soo et al. (1995) ArticleTitleModulation of alpha-interferon’s antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers Antiviral Res 28 IssueID2 121–31 Occurrence Handle10.1016/0166-3542(95)00043-L Occurrence Handle8585766 Occurrence Handle1:CAS:528:DyaK2MXoslGgurw%3D

    Article  PubMed  CAS  Google Scholar 

  8. 8

    AE Munoz D Levi A Podesta JM Gorin J Gonzalez MA Bartellini MS Munne A Cabanne D Flichman R Terg (2000) ArticleTitleInterferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial Gut 46 IssueID3 427–31 Occurrence Handle10.1136/gut.46.3.427 Occurrence Handle10673309 Occurrence Handle1:CAS:528:DC%2BD3cXhvFeksL8%3D

    Article  PubMed  CAS  Google Scholar 

  9. 9

    DA Cameron MC Cornbleet RM Mackie JA Hunter M Gore B Hancock et al. (2001) ArticleTitleAdjuvant interferon alpha 2b in high risk melanoma – the Scottish study Br J Cancer 84 IssueID9 1146–9 Occurrence Handle10.1054/bjoc.2000.1623 Occurrence Handle11379605 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Olurs%3D

    Article  PubMed  CAS  Google Scholar 

  10. 10

    S Negrier B Escudier C Lasset JY Douillard J Savary C Chevreau et al. (1998) ArticleTitleRecombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal-cell carcinoma N Engl J Med 338 IssueID18 1272–8 Occurrence Handle10.1056/NEJM199804303381805 Occurrence Handle9562581 Occurrence Handle1:CAS:528:DyaK1cXivF2qt74%3D

    Article  PubMed  CAS  Google Scholar 

  11. 11

    R Motzer BA Murphy J Bacik et al. (2000) ArticleTitlePhase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 18 IssueID16 2972–80 Occurrence Handle10944130 Occurrence Handle1:CAS:528:DC%2BD3cXmsFSktbc%3D

    PubMed  CAS  Google Scholar 

  12. 12

    DS Verma G Spitzer AR Zander JU Gutterman KB McCredie KA Dicke et al. (1981) ArticleTitleHuman leucocyte interferon preparation-mediated block of granulopoietic differentiation in vitro Exp Hematol 9 IssueID1 63–76 Occurrence Handle6165602 Occurrence Handle1:CAS:528:DyaL3MXhtF2htbY%3D

    PubMed  CAS  Google Scholar 

  13. 13

    JA Ortega A Ma NA Shore PP Dukes TC Merigan et al. (1979) ArticleTitleSuppressive effect of interferon on erythroid cell proliferation Exp Hematol 7 IssueID3 145–9 Occurrence Handle446582 Occurrence Handle1:CAS:528:DyaE1MXksFCnu74%3D

    PubMed  CAS  Google Scholar 

  14. 14

    D Chakrabarti B Hultgren TA Stewart (1996) ArticleTitleIFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B72 J Immunol 157 IssueID2 522–8 Occurrence Handle8752897 Occurrence Handle1:CAS:528:DyaK28XktVyns70%3D

    PubMed  CAS  Google Scholar 

  15. 15

    H Nishiwaki Y Ogura K Miyamoto N Matsuda Y Honda (1996) ArticleTitleInterferon alfa induces leucocyte capillary trapping in rat retinal microcirculation Arch Ophthalmol 114 IssueID6 726–30 Occurrence Handle8639086 Occurrence Handle1:CAS:528:DyaK28XjvFygtrs%3D

    PubMed  CAS  Google Scholar 

  16. 16

    H Gutman J Schachter E Stopel R Gutman J Lahav (2002) ArticleTitleImpaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy Cancer 94 IssueID3 780–5 Occurrence Handle10.1002/cncr.10261 Occurrence Handle11857313 Occurrence Handle1:CAS:528:DC%2BD38XhsVOjurY%3D

    Article  PubMed  CAS  Google Scholar 

  17. 17

    N Kontorinis K Agarwal DT Dieterich (2004) ArticleTitleCurrent status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin Rev Gastroenterol Disord 4 IssueIDSuppl 1 S39–47 Occurrence Handle15184822

    PubMed  Google Scholar 

  18. 18

    S Ariad E Song R Cohen WR Bezwoda (1992) ArticleTitleInterferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T-lymphocytes Mol Biother 4 IssueID3 139–42 Occurrence Handle1445668 Occurrence Handle1:STN:280:DyaK3s%2FnsFCktw%3D%3D

    PubMed  CAS  Google Scholar 

  19. 19

    M Islam RF Frye TJ Richards I Sbeitan SS Donnelly P Glue et al. (2002) ArticleTitleDifferential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs Clin Cancer Res 8 IssueID8 2480–7 Occurrence Handle12171873 Occurrence Handle1:CAS:528:DC%2BD38XmvVaiurY%3D

    PubMed  CAS  Google Scholar 

  20. 20

    RJ Gralla D Osoba MG Kris P Kirkbride PJ Hesketh LW Chinnery et al. (1999) ArticleTitleRecommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology J Clin Oncol 17 IssueID9 2971–94 Occurrence Handle10561376 Occurrence Handle1:STN:280:DC%2BD3c%2FjtVWjtw%3D%3D

    PubMed  CAS  Google Scholar 

  21. 21

    CR Plata-Samalán (2001) ArticleTitleCytokines and feeding Int J Obes 25 IssueIDSuppl 5 S4–S52

    Google Scholar 

  22. 22

    E Dieperink M Willenbring SB Ho (2000) ArticleTitleNeuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review Am J Psychiatr 157 IssueID6 867–76 Occurrence Handle10.1176/appi.ajp.157.6.867 Occurrence Handle10831463 Occurrence Handle1:STN:280:DC%2BD3c3pt1Ogtg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  23. 23

    AR Gool ParticleVan WH Kruit FK Engels G Stoter M Bannink AM Eggermont (2003) ArticleTitleNeuropsychiatric side effects of interferon-alfa therapy Pharm World Sci 25 IssueID1 11–20 Occurrence Handle12661471

    PubMed  Google Scholar 

  24. 24

    F Adams F Fernandez G Mavligit (1988) ArticleTitleInterferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities J Neurooncol 6 IssueID4 355–9 Occurrence Handle10.1007/BF00177432 Occurrence Handle2464673 Occurrence Handle1:STN:280:DyaL1M7isFSntA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  25. 25

    O Merimsky I Reider-Groswasser M Inbar S Chaitchik (1990) ArticleTitleInterferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma Eur J Cancer 26 IssueID5 596–600 Occurrence Handle2144747 Occurrence Handle1:STN:280:DyaK3czotVCksA%3D%3D

    PubMed  CAS  Google Scholar 

  26. 26

    M Schaefer M Schwaiger M Pich K Lieb A Heinz (2003) ArticleTitleNeurotransmitter changes by interferon-alpha and therapeutic implications Pharmacopsychiatry 36 IssueIDSuppl 3 S203–6 Occurrence Handle14677080 Occurrence Handle1:CAS:528:DC%2BD2cXhtVSitLc%3D

    PubMed  CAS  Google Scholar 

  27. 27

    E Suzuki G Yagi T Nakaki S Kanba M Asai (2001) ArticleTitleElevated plasma nitrate levels in depressive states J Affect Disord 63 IssueID1–3 221–4 Occurrence Handle11246099 Occurrence Handle1:CAS:528:DC%2BD3MXlt1yktbc%3D

    PubMed  CAS  Google Scholar 

  28. 28

    Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatr 2004 Oct 19; [Epub ahead of print]

  29. 29

    L Capuron AH Miller (2004) ArticleTitleCytokines and psychopathology: lessons from interferon-α Biol Psychiatr 56 819–24 Occurrence Handle10.1016/j.biopsych.2004.02.009 Occurrence Handle1:CAS:528:DC%2BD2cXhtVCktL7N

    Article  CAS  Google Scholar 

  30. 30

    J Licino MA Kling P Hauser (1998) ArticleTitleCytokines and brain function: relevance to interferon-α-induced mood and cognitive changes Semin Oncol 25 IssueID1 30–8

    Google Scholar 

  31. 31

    MW Fried (2002) ArticleTitleSide effects of therapy of hepatitis C and their management Hepatology 36 IssueID5 Suppl 1 S237–44 Occurrence Handle12407599

    PubMed  Google Scholar 

  32. 32

    A Lucía C Earnest M Pérez (2003) ArticleTitleCancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol 4 IssueID10 616–25 Occurrence Handle14554239

    PubMed  Google Scholar 

  33. 33

    U Reinhold C Hartl R Hering A Hoeft HW Kreysel (1997) ArticleTitleFatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma Lancet 349 IssueID9051 540–1 Occurrence Handle10.1016/S0140-6736(97)80091-8 Occurrence Handle9048796 Occurrence Handle1:STN:280:DyaK2s3gtV2ltQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  34. 34

    GJ Londen Particlevan B Mascarenhas JM Kirkwood (2001) ArticleTitleRhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI J Clin Oncol 19 IssueID17 3794 Occurrence Handle11533109

    PubMed  Google Scholar 

  35. 35

    M Gabrielli L Santarelli M Serricchio D Leo P Pola A Gasbarrini (2003) ArticleTitleAcute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C Am J Gastroenterol 98 IssueID4 940 Occurrence Handle12738487

    PubMed  Google Scholar 

  36. 36

    AO Shakil AM Bisceglie ParticleDi JH Hoofnagle (1996) ArticleTitleSeizures during alpha interferon therapy J Hepatol 24 IssueID1 48–51 Occurrence Handle10.1016/S0168-8278(96)80185-1 Occurrence Handle8834024 Occurrence Handle1:CAS:528:DyaK28Xhs1Sls70%3D

    Article  PubMed  CAS  Google Scholar 

  37. 37

    DA Anthoney I Bone TR Evans (2000) ArticleTitleInflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma Ann Oncol 11 IssueID9 1197–2000 Occurrence Handle10.1023/A:1008362714023 Occurrence Handle11061619 Occurrence Handle1:STN:280:DC%2BD3crgvFWmtg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  38. 38

    MN Meriggioli J Rowin (2000) ArticleTitleChronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha Muscle Nerve 23 IssueID3 433–5 Occurrence Handle10.1002/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O Occurrence Handle10679722 Occurrence Handle1:STN:280:DC%2BD3c7ks1Snsg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  39. 39

    M Maeda N Ohkoshi S Hisahara H Mizusawa S Shoji (1995) ArticleTitleMononeuropathy multiplex in a patient receiving interferon alpha therapy for chronic hepatitis C Rinsho Shinkeigaku 35 IssueID9 1048–50 Occurrence Handle8565346 Occurrence Handle1:STN:280:DyaK287lsFemtw%3D%3D

    PubMed  CAS  Google Scholar 

  40. 40

    A Tunca M Erbayrak S Aytac C Turkay (2004) ArticleTitleAxonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report Turk J Gastroenterol 15 IssueID2 97–9 Occurrence Handle15334319

    PubMed  Google Scholar 

  41. 41

    O Ogundipe M Smith (2000) ArticleTitleBell’s palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders Haemophilia 6 IssueID2 110–2 Occurrence Handle10.1046/j.1365-2516.2000.00391.x Occurrence Handle10781198 Occurrence Handle1:STN:280:DC%2BD3c3ksVSgug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  42. 42

    Y Fukumoto T Shigemitsu N Kajii R Omura T Harada K Okita (1994) ArticleTitleAbducent nerve paralysis during interferon alpha-2a therapy in a case of chronic active hepatitis C Intern Med 33 IssueID10 637–40 Occurrence Handle7827383 Occurrence Handle1:STN:280:DyaK2M7ivVSmtQ%3D%3D

    PubMed  CAS  Google Scholar 

  43. 43

    I Kataoka K Shinagawa Y Shiro S Okamoto R Watanabe T Mori et al. (2002) ArticleTitleMultiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia Am J Hematol 70 IssueID2 149–53 Occurrence Handle10.1002/ajh.10090 Occurrence Handle12111789

    Article  PubMed  Google Scholar 

  44. 44

    T Matsuo R Takabatake (2002) ArticleTitleMultiple sclerosis-like disease secondary to alpha interferon Ocul Immunol Inflamm 10 IssueID4 299–304 Occurrence Handle12854039 Occurrence Handle10.1076/ocii.10.4.299.15588

    PubMed  Article  Google Scholar 

  45. 45

    AP Batocchi A Evoli S Servidei MT Palmisani F Apollo P Tonali (1995) ArticleTitleMyasthenia gravis during interferon alfa therapy Neurology 45 IssueID2 382–3 Occurrence Handle7854543 Occurrence Handle1:STN:280:DyaK2M7lslOltg%3D%3D

    PubMed  CAS  Google Scholar 

  46. 46

    G Mase M Zorzon E Biasutti B Vitrani G Cazzato F Urban et al. (1996) ArticleTitleDevelopment of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis J Neurol Neurosurg Psychiatr 60 IssueID3 348–9 Occurrence Handle8609521 Occurrence Handle1:STN:280:DyaK283gvVeqtg%3D%3D

    PubMed  CAS  Google Scholar 

  47. 47

    D Rohde U Sliwka K Schweizer G Jakse (1996) ArticleTitleOculo-bulbar myasthenia gravis induced by cytokine treatment of a patient with metastasized renal cell carcinoma Eur J Clin Pharmacol 50 IssueID6 471–3 Occurrence Handle10.1007/s002280050143 Occurrence Handle8858274 Occurrence Handle1:STN:280:DyaK2s%2FhtFaltg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  48. 48

    F Bailly A Mattei SN SiAhmed C Trepo (1997) ArticleTitleUncommon side-effects of interferon J Viral Hepat 4 IssueIDSuppl 1 89–94 Occurrence Handle9097285

    PubMed  Google Scholar 

  49. 49

    Y Kanda K Shigeno N Kinoshita K Nakao M Yano H Matsuo (1994) ArticleTitleSudden hearing loss associated with interferon Lancet 343 IssueID8906 1134–5 Occurrence Handle10.1016/S0140-6736(94)90237-2 Occurrence Handle7910234 Occurrence Handle1:STN:280:DyaK2c3jvFSgsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  50. 50

    JR Quesada M Talpaz A Rios R Kurzrock JU Gutterman (1986) ArticleTitleClinical toxicity of interferons in cancer patients: a review J Clin Oncol 4 IssueID7 234–43 Occurrence Handle2418169 Occurrence Handle1:STN:280:DyaL287hsVWmtA%3D%3D

    PubMed  CAS  Google Scholar 

  51. 51

    RA Wilson (2002) ArticleTitleNephrotoxicity of interferon-alfa-ribavarin therapy for chronic hepatitis C J Clin Gastroenterol 35 IssueID1 89–92

    Google Scholar 

  52. 52

    M Sonnenblick A Rosin (1991) ArticleTitleCardiotoxicity of interferon. A review of 44 cases Chest 99 IssueID3 557–61 Occurrence Handle1704826 Occurrence Handle1:STN:280:DyaK3M7jvVeltQ%3D%3D

    PubMed  CAS  Google Scholar 

  53. 53

    Y Kondo M Yukinaka M Nomura Y Nakaya S Ito (2000) ArticleTitleEarly diagnosis of interferon-induced myocardial disorder in patients with chronic hepatitis C: evaluation by myocardial imaging with 123I-BMIPP J Gastroenterol 35 IssueID2 127–35 Occurrence Handle10.1007/s005350050025 Occurrence Handle10680668 Occurrence Handle1:CAS:528:DC%2BD3cXhtFSnsLs%3D

    Article  PubMed  CAS  Google Scholar 

  54. 54

    H Salman M Bergman H Bessler S Alexandrova M Djaldetti (1999) ArticleTitleThe effect of interferon on mouse myocardial capillaries: an ultrastructural study Cancer 85 IssueID6 1375–9 Occurrence Handle10.1002/(SICI)1097-0142(19990315)85:6<1375::AID-CNCR22>3.0.CO;2-D Occurrence Handle10189145 Occurrence Handle1:CAS:528:DyaK1MXitVCjsr8%3D

    Article  PubMed  CAS  Google Scholar 

  55. 55

    C Fernandez-Miranda G Castellano C Guijarro I Fernandez N Schoebel et al. (1998) ArticleTitleLipoprotein changes in patients with chronic hepatitis C treated with interferon-α Am J Gastroenterol 93 IssueID10 1901–4 Occurrence Handle10.1111/j.1572-0241.1998.00546.x Occurrence Handle9772052 Occurrence Handle1:CAS:528:DyaK1cXmvFWltbk%3D

    Article  PubMed  CAS  Google Scholar 

  56. 56

    WHJ Kruit AMM Eggermont G Stoter (2000) ArticleTitleInterferon-α induced Raynaud’s syndrome Ann Oncol 11 IssueID11 1501–2 Occurrence Handle10.1023/A:1026586629166 Occurrence Handle11142493 Occurrence Handle1:STN:280:DC%2BD3M7lt12quw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  57. 57

    H Al-Zahrani V Gupta MD Minden HA Messner JH Lipton (2003) ArticleTitleVascular events associated with alpha interferon therapy Leuk Lymphoma 44 IssueID3 471–5 Occurrence Handle10.1080/1042819021000055066 Occurrence Handle12688317 Occurrence Handle1:CAS:528:DC%2BD38XptlymsLw%3D

    Article  PubMed  CAS  Google Scholar 

  58. 58

    T Kawano M Shigehira H Uto T Nakama J Kato K Hayashi et al. (1996) ArticleTitleRetinal complications during interferon therapy for chronic hepatitis C Am J Gastroenterol 91 IssueID2 309–13 Occurrence Handle8607498 Occurrence Handle1:CAS:528:DyaK28XhvVWnt7g%3D

    PubMed  CAS  Google Scholar 

  59. 59

    HF Dvorak I Gresser (1989) ArticleTitleMicrovascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice J Natl Cancer Inst 81 IssueID7 497–502 Occurrence Handle2921774 Occurrence Handle1:CAS:528:DyaL1MXitFSlsr4%3D

    PubMed  CAS  Google Scholar 

  60. 60

    P Anderson M Höglund S Rödjer (2003) ArticleTitlePulmonary side-effects of interferon-alpha therapy in patients with hematological malignancies Am J Hematol 73 IssueID1 54–8 Occurrence Handle10.1002/ajh.10319 Occurrence Handle12701122

    Article  PubMed  Google Scholar 

  61. 61

    K Ogata T Koga K Yagawa (1994) ArticleTitleInterferon-related bronchiolitis obliterans organizing pneumonia Chest 106 IssueID2 612–3 Occurrence Handle7774350 Occurrence Handle1:STN:280:DyaK2M3pt1Kqtw%3D%3D

    PubMed  CAS  Google Scholar 

  62. 62

    A Takeda K Ikegame Y Kimura H Ogawa S Kanazawa H Nakamura (2000) ArticleTitlePleural effusion during interferon treatment for chronic hepatitis C Hepatogastroenterology 47 IssueID35 1431–5 Occurrence Handle11100369 Occurrence Handle1:STN:280:DC%2BD3Mzgs12htg%3D%3D

    PubMed  CAS  Google Scholar 

  63. 63

    P Fabris A Floreani G Tositti D Vergani F Lalla ParticleDe C Betterle (2003) ArticleTitleType 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy Aliment Pharmacol Ther 18 IssueID6 549–58 Occurrence Handle10.1046/j.1365-2036.2003.01681.x Occurrence Handle12969081 Occurrence Handle1:CAS:528:DC%2BD3sXos1Clu70%3D

    Article  PubMed  CAS  Google Scholar 

  64. 64

    H Gisslinger T Svoboda M Clodi B Gilly H Ludwig L Havelec et al. (1993) ArticleTitleInterferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro Neuroendocrinology 57 IssueID3 489–95 Occurrence Handle8391662 Occurrence Handle1:CAS:528:DyaK3sXitlajs70%3D

    PubMed  CAS  Google Scholar 

  65. 65

    VA Koivisto R Pelkonen K Cantell (1989) ArticleTitleEffect of interferon on glucose tolerance and insulin sensitivity Diabetes 38 IssueID5 641–7 Occurrence Handle2653935 Occurrence Handle1:CAS:528:DyaL1MXktVGls78%3D

    PubMed  CAS  Google Scholar 

  66. 66

    Y Ito N Takeda M Ishimori A Akai K Miura K Yasuda (1999) ArticleTitleEffects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C J Hepatol 31 IssueID2 215–20 Occurrence Handle10.1016/S0168-8278(99)80216-5 Occurrence Handle10453932 Occurrence Handle1:CAS:528:DyaK1MXltFOktrY%3D

    Article  PubMed  CAS  Google Scholar 

  67. 67

    EP Corssmit E Endert HP Sauerwein JA Romijn (2000) ArticleTitleAcute effects of interferon-alpha administration on testosterone concentrations in healthy men Eur J Endocrin 143 IssueID3 371–4 Occurrence Handle1:CAS:528:DC%2BD3cXntVShs74%3D Occurrence Handle10.1530/eje.0.1430371

    CAS  Article  Google Scholar 

  68. 68

    LB Concha HE Carlson A Heimann GV Lake-Bakaar AF Paal (2003) ArticleTitleInterferon-induced hypopituitarism Am J Med 114 IssueID2 161–3 Occurrence Handle10.1016/S0002-9343(02)01323-2 Occurrence Handle12586243

    Article  PubMed  Google Scholar 

  69. 69

    N Sakane T Yoshida K Yoshioka T Umekawa M Kondo A Shimatsu (1995) ArticleTitleReversible hypopituitarism after interferonalfa therapy Lancet 345 IssueID8960 1305 Occurrence Handle10.1016/S0140-6736(95)90950-8 Occurrence Handle7746073 Occurrence Handle1:STN:280:DyaK2M3msVygtA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  70. 70

    NI Weijl D Harts ParticleVan der A Brand Y Kooy S Luxemburg ParticleVan J Schroder et al. (1993) ArticleTitleHypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment J Clin Oncol 11 IssueID7 1376–83 Occurrence Handle8315436 Occurrence Handle1:STN:280:DyaK3szgtFKktw%3D%3D

    PubMed  CAS  Google Scholar 

  71. 71

    TM Bell AS Bansal C Shorthouse N Sandford EE Powell (1999) ArticleTitleLow-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C J Gastroenterol Hepatol 14 IssueID5 419–22 Occurrence Handle10.1046/j.1440-1746.1999.01896.x Occurrence Handle10355504 Occurrence Handle1:CAS:528:DyaK1MXjs1yis78%3D

    Article  PubMed  CAS  Google Scholar 

  72. 72

    U Watanabe E Hashimoto T Hisamitsu H Obata N Hayashi (1994) ArticleTitleThe risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C Am J Gastroenterol 89 IssueID3 399–403 Occurrence Handle8122653 Occurrence Handle1:STN:280:DyaK2c7mvVWkuw%3D%3D

    PubMed  CAS  Google Scholar 

  73. 73

    T Vial J Descotes (1995) ArticleTitleImmune-mediated side-effects of cytokines in humans Toxicology 105 IssueID1 31–57 Occurrence Handle10.1016/0300-483X(95)03124-X Occurrence Handle8638283 Occurrence Handle1:CAS:528:DyaK2MXpsFSisLg%3D

    Article  PubMed  CAS  Google Scholar 

  74. 74

    N Lahat M Sheinfeld E Sobel A Kinarty Z Kraiem (1992) ArticleTitleDivergent effects of cytokines on human leucocyte antigen-DR antigen expression of neoplastic and non-neoplastic human thyroid cells Cancer 69 IssueID7 1799–807 Occurrence Handle1551065 Occurrence Handle1:CAS:528:DyaK38XktVGrsrs%3D

    PubMed  CAS  Google Scholar 

  75. 75

    X You W Teng Z Shan (1999) ArticleTitleExpression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha Chin Med J 112 IssueID1 61–6 Occurrence Handle11593644 Occurrence Handle1:CAS:528:DyaK1MXhsFShu7c%3D

    PubMed  CAS  Google Scholar 

  76. 76

    S Kakizaki H Takagi M Murakami H Takayama M Mori (1999) ArticleTitleHLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C J Hepatol 30 IssueID5 794–800 Occurrence Handle10.1016/S0168-8278(99)80131-7 Occurrence Handle10365804 Occurrence Handle1:STN:280:DyaK1M3ptF2htA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  77. 77

    C Carella G Mazziotti F Morisco G Manganella M Rotondi C Tucillo et al. (2001) ArticleTitleLong-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment J Clin Endocrinol Metab 86 IssueID5 1925–9 Occurrence Handle10.1210/jc.86.5.1925 Occurrence Handle11344186 Occurrence Handle1:CAS:528:DC%2BD3MXjs1OmsL8%3D

    Article  PubMed  CAS  Google Scholar 

  78. 78

    B Guillot L Blazquez D Bessis O Dereure JJ Guilhou (2004) ArticleTitleA prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma Dermatology 208 IssueID1 49–54 Occurrence Handle10.1159/000075046 Occurrence Handle14730237 Occurrence Handle1:CAS:528:DC%2BD2cXkt1yqtg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  79. 79

    GN Dalekos J Hatzis EV Tsianos (1998) ArticleTitleDermatologic disease during interferon-alpha therapy for chronic viral hepatitis Ann Intern Med 128 IssueID5 409–10 Occurrence Handle9490605 Occurrence Handle1:STN:280:DyaK1c7jvVyhuw%3D%3D

    PubMed  CAS  Google Scholar 

  80. 80

    LA Asnis AA Gaspari (1995) ArticleTitleCutaneous reactions to recombinant cytokine therapy J Am Acad Dermatol 33 IssueID3 393–410 Occurrence Handle10.1016/0190-9622(95)91382-3 Occurrence Handle7544812 Occurrence Handle1:STN:280:DyaK2Mzos1OmsQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  81. 81

    PJ Rowan S Tabasi M Abdul-Latif ME Kunik HB El-Serag (2004) ArticleTitlePsychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C J Clin Gastroenterol 38 IssueID6 530–4 Occurrence Handle15220690

    PubMed  Google Scholar 

  82. 82

    JM Loftis P Hauser (2004) ArticleTitleThe phenomenology and treatment of interferon-induced depression J Affect Disord 82 IssueID2 175–90 Occurrence Handle10.1016/j.jad.2004.04.002 Occurrence Handle15488246 Occurrence Handle1:CAS:528:DC%2BD2cXos1ens7g%3D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stefan Sleijfer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sleijfer, S., Bannink, M., Van Gool, A. . et al. Side Effects of Interferon-α Therapy. Pharm World Sci 27, 423 (2005). https://doi.org/10.1007/s11096-005-1319-7

Download citation

Keywords

  • Hepatitis
  • Interferon-α
  • Melanoma
  • Pathophysiology
  • Renal cell carcinoma
  • Side effects